Nutriband (NASDAQ:NTRB) Research Coverage Started at Noble Financial

Noble Financial initiated coverage on shares of Nutriband (NASDAQ:NTRB) in a report released on Wednesday morning, Marketbeat.com reports. The brokerage issued an outperform rating and a $13.00 target price on the stock. Noble Financial also issued estimates for Nutriband’s Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.60) EPS, Q1 2026 earnings at ($0.13) EPS, Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.56) EPS, FY2027 earnings at $1.45 EPS and FY2028 earnings at $3.66 EPS.

Nutriband Stock Performance

NTRB stock opened at $8.53 on Wednesday. Nutriband has a twelve month low of $2.22 and a twelve month high of $11.78. The company has a quick ratio of 4.83, a current ratio of 4.96 and a debt-to-equity ratio of 0.01. The company has a market cap of $94.77 million, a P/E ratio of -12.01 and a beta of 0.99. The business’s fifty day moving average is $4.59 and its 200-day moving average is $5.44.

Nutriband (NASDAQ:NTRB) last released its earnings results on Tuesday, December 3rd. The company reported ($0.12) earnings per share for the quarter. Nutriband had a negative net margin of 338.51% and a negative return on equity of 54.49%.

About Nutriband

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.